DCTD Functional Genomics

该项目是癌症治疗和诊断部门内的发展治疗计划药物发现和开发计划的主要部分。重点是临床前药物发现和临床前药物开发。 功能基因组学实验室（LFG） 功能基因组学实验室（LFG）为筛选技术分支（STB）、开发治疗学项目（DTP）、药物发现和开发工作提供专门的研究支持。基因组技术，包括寡核苷酸微阵列、TaqMan（R）实时PCR、报告基因测定、多重基因测定和RNAi，被用作确定特定基因在药物作用机制中的作用的工具。这些方法提供了一个重要的资源，以探索新的药物的作用机制的初步见解，或在更先进的阶段与临床前药物的详细分析。该实验室为小企业或校外和校内科学家提供了一个资源，以合作将新药推向临床。此外，在这一领域获得的专业知识使实验室能够在提出一个以NCI-60细胞系筛选中药物反应基因谱为中心的大规模项目中发挥关键作用。此外，根据DTP或临床治疗评价计划（CTEP）的要求，LFG还提供了临床前体外药物联合研究，以评价潜在临床药物联合的可能理想或不理想的相互作用。

This project is a major part of the Developmental Therapeutics Program drug discovery and development program within the Division of Cancer Treatment and Diagnosis. The emphasis is on preclinical drug discovery and preclinical drug development. LABORATORY OF FUNCTIONAL GENOMICS (LFG) The Laboratory of Functional Genomics (LFG) provides dedicated research support for the Screening Technologies Branch (STB), Developmental Therapeutics Program (DTP), drug discovery and development effort. Genomic techniques, including oligonucleotide microarrays, TaqMan(R) real-time PCR, reporter gene assays, mutiplexing gene assays, and RNAi are used as tools to determine the role of specific genes in the mechanisms of drug action. These methods have provided an important resource to probe for preliminary insights into mechanism of action of novel agents, or detailed analyses with preclinical drugs at a more advanced stage. The laboratory offers a resource for small businesses or extra- and intramural scientists to collaborate in an effort to bring new drugs to the clinic. Moreover, the expertise gained in this area has allowed the laboratory to play a critical role in proposing a large-scale project centered on gene profiling of drug responses in the NCI-60 cell line screen. In addition, the LFG provides preclinical, in vitro drug combination studies for evaluation of possible desirable or undesirable interactions for potential clinical drug combinations, as requested by DTP or the Clinical Therapy Evaluation Program (CTEP).